|Dr. Stephen J. Farr||Co-Founder, CEO, Pres & Director||869.7k||12.51k||1959|
|Mr. Michael P. Smith||Exec. VP, CFO, Treasurer & Sec.||572.33k||N/A||1968|
|Dr. Bradley S. Galer||Exec. VP & Chief Medical Officer||587.95k||N/A||1962|
|Dr. Gail M. Farfel||Exec. VP & Chief Devel. Officer||574.1k||867.89k||1964|
|Mr. Ashish M. Sagrolikar||Exec. VP & Chief Commercial Officer||557.7k||N/A||N/A|
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Zogenix, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 6. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 7; Compensation: 7.